VOTRIENT Drug Patent Profile
✉ Email this page to a colleague
When do Votrient patents expire, and what generic alternatives are available?
Votrient is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in VOTRIENT is pazopanib hydrochloride. There are five drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the pazopanib hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Votrient
A generic version of VOTRIENT was approved as pazopanib hydrochloride by APOTEX on October 19th, 2023.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VOTRIENT?
- What are the global sales for VOTRIENT?
- What is Average Wholesale Price for VOTRIENT?
Summary for VOTRIENT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 102 |
| Clinical Trials: | 104 |
| Patent Applications: | 518 |
| Drug Prices: | Drug price information for VOTRIENT |
| What excipients (inactive ingredients) are in VOTRIENT? | VOTRIENT excipients list |
| DailyMed Link: | VOTRIENT at DailyMed |
Recent Clinical Trials for VOTRIENT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Medical Center Groningen | Phase 4 |
| Centre Leon Berard | Phase 1/Phase 2 |
| National Cancer Institute, France | Phase 1/Phase 2 |
Pharmacology for VOTRIENT
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Cytochrome P450 2C8 Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors Protein Kinase Inhibitors |
US Patents and Regulatory Information for VOTRIENT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VOTRIENT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VOTRIENT
See the table below for patents covering VOTRIENT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hong Kong | 1059926 | ⤷ Sign Up | |
| Germany | 60138645 | ⤷ Sign Up | |
| Canada | 2432000 | PYRIMIDINEAMINES COMME MODULATEURS DE L'ANGIOGENESE (PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS) | ⤷ Sign Up |
| Poland | 363243 | ⤷ Sign Up | |
| Portugal | 1343782 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VOTRIENT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1343782 | SPC025/2010 | Ireland | ⤷ Sign Up | SPC025/2010: 20110401, EXPIRES: 20250613 |
| 1343782 | CA 2010 00024 | Denmark | ⤷ Sign Up | PRODUCT NAME: PAZOPANIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER HYDROCLORID |
| 1343782 | SPC/GB10/032 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: PAZOPANIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU 1/10/628/001 20100614; UK EU 1/10/628/002 20100614; UK EU 1/10/628/003 20100614; UK EU 1/10/628/004 20100614 |
| 1343782 | 122010000038 | Germany | ⤷ Sign Up | PRODUCT NAME: PAZOPANIB ODER EIN SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614 |
| 1343782 | 28/2010 | Austria | ⤷ Sign Up | PRODUCT NAME: PAZOPANIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/10/628/001 - EU/1/10/628/004 20100614 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
